Am­gen ex­tends au­toim­mune pact with small Michi­gan biotech

Am­gen is go­ing all in on a three-in­di­ca­tion col­lab­o­ra­tion with an Ann Ar­bor, MI biotech.

The Cal­i­for­nia phar­ma has elect­ed to move for­ward with all three au­toim­mune pro­grams in its $240 mil­lion pact with EVOQ Ther­a­peu­tics, the com­pa­nies said Wednes­day. EVOQ re­ceived an undis­closed mile­stone pay­ment.

The duo ini­tial­ly teamed up in Jan­u­ary 2021. Since then, the start­up from the Uni­ver­si­ty of Michi­gan and Lawrence Liv­er­more Na­tion­al Lab­o­ra­to­ry has al­so al­lied with the non­prof­it JDRF on type 1 di­a­betes and, in re­cent weeks, with Gilead for rheuma­toid arthri­tis and lu­pus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA